– the leading provider of online annual reports to individual and institutional investors.


Hybrigenics SA, a biotechnology and pharmaceutical company, engages in the research and development of programs focused on targets and therapies for the treatment of cancer. Its development program is based on Inecalcitol, a phase II synthetic chemical derivative of calcitriol, the naturally active form of vitamin D, for the treatment of hormone-refractory prostate cancer.

View Online Reports: Order Free Hardcopy You can request a free hardcopy of this report mailed to you by clicking the button below.
Add Annual Report

No investor fact sheets added yet
No responsibility reports added yet

Browse Reports